A "Watch and Wait" Strategy Involving Regular Endoscopic Surveillance Is Safe for Many Patients with Small, Sporadic, Grade 1, Non-Ampullary, Non-Functioning Duodenal Neuroendocrine Tumours

被引:14
作者
Exarchou, Klaire [1 ,2 ]
Moore, Andrew R. [3 ]
Smart, Howard L. [3 ]
Duckworth, Carrie A. [4 ]
Howes, Nathan [2 ]
Pritchard, D. Mark [1 ,3 ]
机构
[1] Univ Liverpool, Dept Mol & Clin Canc Med, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England
[2] Liverpool Univ Hosp NHS Fdn Trust, bDept Upper Gastrointestinal Surg, Liverpool, Merseyside, England
[3] Liverpool Univ Hosp NHS Fdn Trust, Dept Gastroenterol, Liverpool, Merseyside, England
[4] Univ Liverpool, Inst Syst Mol & Integrat Biol, Dept Mol Physiol & Cell Signalling, Liverpool, Merseyside, England
关键词
Neuroendocrine tumour; Surveillance; Carcinoid; Endoscopy; CARCINOID-TUMORS; CHROMOGRANIN-A; FOLLOW-UP; DIAGNOSIS; MANAGEMENT; VATER;
D O I
10.1159/000511613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Duodenal neuroendocrine tumours (d-NETs) are rare but are increasing in incidence. Current ENETS guidelines advocate resection of all localized d-NETs. However, "watch and wait" may be appropriate for some localized, small, grade 1, non-functioning, non-ampullary d-NETs. We evaluated whether patients with such d-NETs who chose "watch and wait" involving regular endoscopic surveillance had equivalent disease-related outcomes to patients undergoing endoscopic or surgical resection. Methods: Retrospective review of patients with histologically confirmed d-NETs at Liverpool ENETS Centre of Excellence 2007-2020. Results: Sixty-nine patients were diagnosed with d-NET of which 50 were sporadic, non-functioning, non-ampullary tumours. Patient treatment groups were similar in terms of age, gender, and tumour location and grade, but unsurprisingly, larger tumours (median diameter 17 mm [p < 0.0001]) were found in the surgically treated group. Five patients underwent surgical resection with no evidence of tumour recurrence or disease-related death. Twelve patients underwent endoscopic resection (ER), with 1 local recurrence detected during follow-up. Thirty patients (28 with d-NETs <= 10 mm) underwent "watch and wait" with resection only if tumours increased in size. The d-NETs in 28/30 patients remained stable or decreased in size over a median 27 months (IQR: 15-48, R: 3-98). In 7 patients, the d-NET was completely removed by avulsion during diagnostic biopsy and was not seen at subsequent endoscopies. Only 2 patients showed increased d-NET size during surveillance, of whom only one was fit for ER. No NET-related deaths were documented during follow-up. Conclusions: All of the localized, <= 10 mm, grade 1, non-functioning, non-ampullary d-NETs in this cohort behaved indolently with very low risks of progression and no tumour-related deaths. "Watch and wait," therefore, appears to be a safe alternative management strategy for selected d-NETs.
引用
收藏
页码:764 / 774
页数:11
相关论文
共 24 条
  • [1] BURKE AP, 1990, ARCH PATHOL LAB MED, V114, P700
  • [2] Neuroendocrine Tumors of the Ampulla of Vater Biological Behavior and Surgical Management
    Carter, Jonathan T.
    Grenert, James P.
    Rubenstein, Laura
    Stewart, Lygia
    Way, Lawrence W.
    [J]. ARCHIVES OF SURGERY, 2009, 144 (06) : 527 - 531
  • [3] Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors
    Cheng, Yuejuan
    Sun, Zhao
    Bai, Chunmei
    Yan, Xiaoyan
    Qin, Ran
    Meng, Changting
    Ying, Hongyan
    [J]. TUMOR BIOLOGY, 2016, 37 (03) : 2863 - 2869
  • [4] Ampullary carcinoid tumors: Rationale for an aggressive surgical approach
    Clements, WM
    Martin, SP
    Stemmerman, G
    Lowy, AM
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (06) : 773 - 776
  • [5] ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms
    Delle Fave, G.
    O'Toole, D.
    Sundin, A.
    Taal, B.
    Ferolla, P.
    Ramage, J. K.
    Ferone, D.
    Ito, T.
    Weber, W.
    Zheng-Pei, Z.
    De Herder, W. W.
    Pascher, A.
    Ruszniewski, P.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 (02) : 119 - 124
  • [6] Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours
    Exarchou, Klaire
    Howes, Nathan
    Pritchard, David Mark
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (12) : 1247 - 1267
  • [7] Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
    Fitzgerald, Timothy L.
    Dennis, Samuel O.
    Kachare, Swapnil D.
    Vohra, Nasreen A.
    Zervos, Emmanuel E.
    [J]. SURGERY, 2015, 158 (02) : 466 - 471
  • [8] Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?
    Gamboa, Adriana C.
    Liu, Yuan
    Lee, Rachel M.
    Zaidi, Mohammad Y.
    Staley, Charles A.
    Kooby, David A.
    Winer, Joshua H.
    Shah, Mihir M.
    Russell, Maria C.
    Cardona, Kenneth
    Maithel, Shishir K.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (08) : 1293 - 1301
  • [9] The Risk Factors for Metastasis in Non-Ampullary Duodenal Neuroendocrine Tumors Measuring 20 mm or Less in Diameter
    Hatta, Waku
    Koike, Tomoyuki
    Iijima, Katsunori
    Asanuma, Kiyotaka
    Asano, Naoki
    Musha, Hiroaki
    Inomata, Yoshifumi
    Sano, Toshikazu
    Endo, Hiroyuki
    Ikehata, Atsushi
    Horii, Toru
    Ohyauchi, Motoki
    Yokosawa, Satoshi
    Kasajima, Atsuko
    Fujishima, Fumiyoshi
    Sasano, Hironobu
    Nakaya, Naoki
    Nakamura, Tomohiro
    Shimosegawa, Tooru
    [J]. DIGESTION, 2017, 95 (03) : 201 - 209
  • [10] Ho Choon-Kiat, 2005, HPB (Oxford), V7, P99, DOI 10.1080/13651820510028936